Rein Therapeutics, Inc. financial data

Symbol
RNTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
12407 N. Mopac Expy., Suite 250 #390, Austin, TX
Fiscal year end
December 31
Former names
Aileron Therapeutics, Inc. (to 12/9/2024), AILERON THERAPEUTICS INC (to 3/29/2024)
Latest financial report
10-K - Q4 2024 - Apr 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 327 % -46.9%
Debt-to-equity 9.82 % -39.5%
Return On Equity -46.1 % +55.3%
Return On Assets -67.1 % -59.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 22M shares +29.6%
Common Stock, Shares, Outstanding 21.7M shares +343%
Entity Public Float 54.1B USD +721%
Common Stock, Value, Issued 108K USD +18.7%
Weighted Average Number of Shares Outstanding, Basic 17.9M shares +290%
Weighted Average Number of Shares Outstanding, Diluted 17.9M shares +290%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 14.2M USD +257%
General and Administrative Expense 13.9M USD +22.1%
Operating Income (Loss) -65.1M USD -300%
Net Income (Loss) Attributable to Parent -62.9M USD -300%
Earnings Per Share, Basic -3.51 USD/shares -2.63%
Earnings Per Share, Diluted -3.51 USD/shares -2.63%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 12.9M USD -25.7%
Cash, Cash Equivalents, and Short-term Investments 13.7M USD -57.8%
Other Assets, Current 676K USD +0.15%
Assets, Current 13.7M USD -25.2%
Property, Plant and Equipment, Net 1K USD -94.7%
Intangible Assets, Net (Excluding Goodwill) 42.2M USD -46.7%
Goodwill 6.33M USD 0%
Other Assets, Noncurrent 2K USD -99.9%
Assets 62.2M USD -41.3%
Accounts Payable, Current 911K USD -23.4%
Employee-related Liabilities, Current 1.47M USD +25.1%
Liabilities, Current 5.75M USD +31.1%
Deferred Income Tax Liabilities, Net 1.77M USD -46.7%
Other Liabilities, Noncurrent 277K USD
Liabilities 7.8M USD +1.13%
Accumulated Other Comprehensive Income (Loss), Net of Tax -18K USD +71.4%
Retained Earnings (Accumulated Deficit) -351M USD -21.8%
Stockholders' Equity Attributable to Parent 54.4M USD -44.7%
Liabilities and Equity 62.2M USD -41.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.27M USD -13.1%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 100M shares +122%
Common Stock, Shares, Issued 21.7M shares +343%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.27M USD -304%
Deferred Tax Assets, Valuation Allowance 30.5M USD +64.6%
Deferred Tax Assets, Gross 37.5M USD +18%
Depreciation 13K USD -13.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -62.8M USD -299%
Property, Plant and Equipment, Gross 377K USD +10.9%
Operating Lease, Liability, Current 48K USD +45.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 48K USD +37.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure -41.7%
Deferred Tax Assets, Operating Loss Carryforwards 17.4M USD +40.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 59K USD +37.2%
Deferred Tax Assets, Net of Valuation Allowance 7.05M USD -46.9%
Share-based Payment Arrangement, Expense 1.12M USD -6.13%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%